Seres Therapeutics Inc [MCRB] stock is trading at $11.87, up 9.30%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MCRB shares have gain 24.82% over the last week, with a monthly amount glided 69.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Seres Therapeutics Inc [NASDAQ: MCRB] stock has seen the most recent analyst activity on May 08, 2025, when Chardan Capital Markets downgraded its rating to a Neutral but kept the price target unchanged to $6 for it. Previously, JP Morgan downgraded its rating to Underweight on October 24, 2024. JP Morgan started tracking the stock assigning a Neutral rating and suggested a price target of $7 on April 21, 2023. Goldman downgraded its rating to a Sell and reduced its price target to $7 on July 23, 2021. In a note dated March 05, 2021, Chardan Capital Markets upgraded an Buy rating on this stock but restated the target price of $30.
Seres Therapeutics Inc [MCRB] stock has fluctuated between $6.53 and $30.60 over the past year. Currently, Wall Street analysts expect the stock to reach $1.25 within the next 12 months. Seres Therapeutics Inc [NASDAQ: MCRB] shares were valued at $11.87 at the most recent close of the market. An investor can expect a potential drop of -89.47% based on the average MCRB price forecast.
Analyzing the MCRB fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at 0.44, Equity is 266.73 and Total Capital is -0.88. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.77.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.98 points at the first support level, and at 10.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.47, and for the 2nd resistance point, it is at 13.07.
Ratios To Look Out For
For context, Seres Therapeutics Inc’s Current Ratio is 2.11. In addition, the Quick Ratio stands at 2.11 and the Cash Ratio stands at 1.88.
Transactions by insiders
Recent insider trading involved Young Teresa L.,, that happened on May 16 ’25 when 63.0 shares were sold. CEO and President, Shaff Eric D. completed a deal on May 16 ’25 to sell 220.0 shares. Meanwhile, Chief Legal Officer and EVP DesRosier Thomas sold 79.0 shares on May 15 ’25.
